[1]李杨东,范毛川,窦启锋.膀胱癌患者来源的异种移植物模型构建与应用研究进展[J].新乡医学院学报,2022,39(10):992-995.[doi:10.7683/xxyxyxb.2022.10.018]
　LI Yangdong,FAN Maochuan,DOU Qifeng.Research progress in the construction and application of xenograft model from patients with bladder cancer[J].Journal of Xinxiang Medical University,2022,39(10):992-995.[doi:10.7683/xxyxyxb.2022.10.018]
点击复制

膀胱癌患者来源的异种移植物模型构建与应用研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年10
页码:
992-995
栏目:
综述
出版日期:
2022-10-05

文章信息/Info

Title:
Research progress in the construction and application of xenograft model from patients with bladder cancer
作者:
李杨东; 范毛川; 窦启锋
(新乡医学院第一附属医院泌尿外科，河南　卫辉　453100)
Author(s):
LI Yangdong; FAN Maochuan; DOU Qifeng
（Department of Urology Surgery，the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100，Henan Province，China）
关键词:
膀胱癌; 异种移植物模型; 临床前研究; 精准医学
Keywords:
bladder cancer; xenograft models; preclinical research; precision medicine
分类号:
R737.14
DOI:
10.7683/xxyxyxb.2022.10.018
文献标志码:
A
摘要:
肿瘤患者来源的异种移植物模型可将肿瘤组织植入免疫缺陷小鼠体内，以保留患者肿瘤的组织学和分子表型特征，进一步再现原发肿瘤的异质性，因此，该模型成为较为可靠的体内人类肿瘤模型，能更加精准地用于开发特定肿瘤生物标志物、创建个体化治疗以及研发治疗癌症的药物。本文就目前有关膀胱癌患者来源的异种移植物模型构建过程中受体动物的选择、移植部位以及该模型的优势与不足等相关研究进展进行综述，以期为其应用于膀胱癌治疗的研究提供参考依据。
Abstract:
The tumor patient-derived xenograft model allows the implantation of tumor tissue into immunodeficient mice to preserve the histological and molecular phenotypic characteristics of tumor and further recapitulate the heterogeneity of the primary tumor.Therefore,this model has become a more reliable human tumor model in vivo,which can be used more precisely for developing specific tumor biomarkers,creating individualized therapies,and developing drugs to treat cancer.This article reviews the current research on the selection of recipient animals,transplantation sites,and the advantages,disadvantages of the xenograft model derived from patients with bladder cancer，so as to provide a reference for the study of its application in the treatment of bladder cancer.

参考文献/References:

［1］　DOBRUCH J,OSZCZUDOWSKI M.Bladder cancer:current challenges and future directions［J］.Medicina (Kaunas),2021,57(8):749.
［2］　周五二，杨成林，王尉，等.抑制 OCT4-pg5 与 OCT4B 表达对膀胱癌顺铂敏感性的影响［J］.解放军医学杂志,2020,45(2):179-181.
ZHOU W E,YANG C L,WANG W，et al.Suppression of OCT4-pg5 and OCT4B enhanced the sensitivity of bladder cancer cells T24 to cisplatin［J］.Med J Chin PLA,2020,45(2):179-181.
［3］　NA D,MOON H G.Patient-derived xenograft models in breast cancer research［J］.Adv Exp Med Biol,2021,1187:283-301.
［4］　LONG Q,MA A H,ZHANG H,et al.Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer［J］.Cancer Immunol Immunother,2020,69(11):2305-2317.
［5］　CAI E Y,GARCIA J,LIU Y,et al.A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture［J］.Sci Rep,2021,11(1):4609.
［6］　TAN P,CAI H,WEI Q,et al.Enhanced chemo-photodynamic therapy of an enzyme-responsive prodrug in bladder cancer patient-derived xenograft models［J］.Biomaterials,2021,277:121061.
［7］　AMARA R,ZIMMERMANN M,MA A H,et al.A simple three-dimensional in vitro culture mimicking the in vivo-like cell behavior of bladder patient-derived xenograft models［J］.Cancers(Basel),2020,12(5):1304.
［8］　NAMEKAWA T,IKEDA K,HORIE-INOUE K,et al.ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression［J］.Int J Cancer,2020,146(4):1099-1113.
［9］　ANNIBALI D,LEUCCI E,HERMANS E,et al.Development of patient-derived tumor xenograft models［J］.Methods Mol Biol,2019,1862:217-225.
［10］　BULLE A,DEKERVEL J,LIBBRECHT L,et al.Gemcitabine induces epithelial-to-mesenchymal transition in patient-derived pancreatic ductal adenocarcinoma xenografts［J］.Am J Transl Res,2019,11(2):765-779.
［11］　谈小倩,瞿伟,李亮,等.几种常用免疫缺陷小鼠的血液学及血液淋巴细胞亚群的测定与比较分析［J］.实验动物与比较医学,2021,41(2):155-160.
TAN X Q,ZHAI W,LI L,et al.Determination and comparative analysis of hematological indexes and percentage of lymphocyte subsets in several immunodeficient mice［J］.Lab Anim Comp Med,2021,41(2):155-160.
［12］　BLINOVA E,DUDINA M O,SUSLOVA I R,et al.Novel amino-chromone derivative inhibits tumor growth on xenograft model of lung cancer in mice［J］.J Adv Pharm Technol Res,2018,9(4):130-134.
［13］　SHI J,LI Y,JIA R,et al.The fidelity of cancer cells in PDX models:characteristics,mechanism and clinical significance［J］.Int J Cancer,2020,146(8):2078-2088.
［14］　CHEN X,SHEN C,WEI Z,et al.Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity［J］.Cancer Biol Med,2021,18(1):184-198.
［15］　LU J H,WANG Y,MENG Q,et al.Establishment of gastric cancer patient-derived xenograft models and primary cell lines［J］.J Vis Exp,2019(149):10.
［16］　SANTIAGO-O′FARRILL J M,WEROHA S J,HOU X,et al.Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells,xenografts,and patient-derived xenograft models［J］.Cancer,2020,126(4):894-907.
［17］　PARK J H,ZHAO M,OSHIRO H,et al.Peritoneal metastases in a patient-derived orthotopic xenograft (PDOX) model of colon cancer imaged non-invasively via red fluorescent protein labeled stromal cells［J］.Anticancer Res,2019,39(7):3463-3467.
［18］　ZOU J,LIU Y,WANG J,et al.Establishment and genomic chara-cterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization［J］.J Transl Med,2018,16(1):15.
［19］　COLLINS A T,LANG S H.A systematic review of the validity of patient derived xenograft (PDX) models:the implications for translational research and personalized medicine［J］.Peer J,2018,6:e5981.
［20］　YOSHIDA G J.Applications of patient-derived tumor xenograft models and tumor organoids［J］.J Hematol Oncol,2020,13(1):4.
［21］　OKADA S,VAETEEWOOTTACHARN K,KARIYA R.Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models［J］.Cells,2019,8(8):889.
［22］　MALETZKI C,BOCK S,FRUH P,et al.NSG mice as hosts for oncological precision medicine［J］.Lab Invest,2020,100(1):27-37.
［23］　ANDERSEN A H F,NIELSEN S S F,OLESEN R,et al.Humani-zed NOG mice for intravaginal HIV exposure and treatment of HIV infection［J］.J Vis Exp,2020(155):10.
［24］　PAN C X,ZHANG H,TEPPER C G,et al.Development and characterization of bladder cancer patient-derived xenografts for molecularly guided targeted therapy［J］.PLoS One,2015,10(8):e134346.
［25］　JGER W,XUE H,HAYASHI T,et al.Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies［J］.Oncotarget,2015,6(25):21522-21532.
［26］　MIRANDA M A,MARCATO P D,MONDAL A,et al.Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells［J］.Mater Sci Eng C Mater Biol Appl,2021,119:111460.
［27］　LEE H W,CHUNG W,LEE H O,et al.Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient［J］.Genome Med,2020,12(1):47.
［28］　RICHTERS A,ABEN K K H,KIEMENEY L A L M.The global burden of urinary bladder cancer:an update［J］.World J Urol,2020,38(8):1895-1904.
［29］　WILLIAMS J A.Using PDX for preclinical cancer drug discovery:the evolving field［J］.J Clin Med,2018,7(3):41.
［30］　YOSHIDA G J.Applications of patient-derived tumor xenograft models and tumor organoids［J］.J Hematol Oncol,2020,13(1):4.
［31］　WEIDON T E,SOLOWAY M S.Susceptibility of urothelium to neoplastic cellular implantation［J］.Urology,1975,5(6):824-827.
［32］　NAMEKAWA T,IKEDA K,HORIE-INOUE K,et al.ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression［J］.Int J Cancer,2020,146(4):1099-1113.
［33］　RISBRIDGER G P,LAWRENCE M G,TAYLOR R A.PDX:moving beyond drug screening to versatile models for research discovery［J］.J Endocr Soc,2020,4(11):bvaa132.
［34］　CIRONE P,ANDRESEN C J,ESWARAKA J R,et al.Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer［J］.Cancer Chemother Pharmacol,2014,73(3):525-538.
［35］　SKOWRON K B,PITRODA S P,NAMM J P,et al.Basal tumor cell isolation and patient-derived xenograft engraftment identify high-risk clinical bladder cancers［J］.Sci Rep,2016,6:35854.
［36］　INVREA F,ROVITO R,TORCHIARO E,et al.Patient-derived xenografts (PDXs) as model systems for human cancer［J］.Curr Opin Biotechnol,2020,63:151-156.
［37］　GOTO T.Patient-derived tumor xenograft models:toward the establishment of precision cancer medicine［J］.J Pers Med,2020,10(3):64.
［38］　XU C,LI X,LIU P,et al.Patient-derived xenograft mouse models:a high fidelity tool for individualized medicine［J］.Oncol Lett,2019,17(1):3-10.
［39］　SHI C,CHEN X,TAN D.Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity［J］.Transl Androl Urol,2019,8(5):519-528.
［40］　MONDAL A M,MA A H,LI G,et al.Fidelity of a PDX-CR model for bladder cancer［J］.Biochem Biophys Res Commun,2019,517(1):49-56.

相似文献/References:

[1]焦亚莉,高恒瑞,黄 臻.膀胱癌中C—erbB一2的表达及其在复发中的意义[J].新乡医学院学报,2002,19(04):300.
[2]张超,杨德林,王剑松,等.高侵袭力人膀胱癌细胞亚系的分离鉴定[J].新乡医学院学报,2008,25(02):130.
[3]王小青,山慈明.膀胱癌术后膀胱灌注患者遵医行为影响因素分析及护理对策[J].新乡医学院学报,2016,33(5):431.[doi:10.7683/xxyxyxb.2016.05.024]
　WANG Xiao-qing,SHAN Ci-ming.Analysis of influencing factors of compliance behavior of patients with bladder irrigation after operation of bladder cancer and the nursing countermeasures[J].Journal of Xinxiang Medical University,2016,33(10):431.[doi:10.7683/xxyxyxb.2016.05.024]

更新日期/Last Update: 2022-10-05